New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml;   - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).

Israel - English - Ministry of Health

medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Singapore - English - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 1000 i.u. per 20ml - human antithrombin 1000 i.u. per 20ml

Singapore - English - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 500 i.u. per 10ml - human antithrombin 500 i.u. per 10ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - laronidase - injection, solution - 2.9mg - laronidase 2.9mg

European Union - English - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mucopolysaccharidosis iv - other alimentary tract and metabolism products, - vimizim is indicated for the treatment of mucopolysaccharidosis, type iva (morquio a syndrome, mps iva) in patients of all ages.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - galsulfase 1 mg/ml - concentrate for infusion - 1 mg/ml - active: galsulfase 1 mg/ml excipient: polysorbate 80 sodium chloride sodium phosphate water for injection - naglazyme is indicated as long term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi, n-acetylgalactosamine 4-sulfatase deficiency, maroteaux-lamy syndrome).

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - 44670 - bladder instillation, barrier - procedure pack consisting of a clear plastic pre-filled syringe containing a sterile aqueous solution of hyaluronic acid sodium salt (1.6%), sodium chondroitin sulphate (2%) and calcium chloride administered as a bladder instillation via connection to a catheter using the leur lock adaptor and the ialuadapter included in the pack. the ialuadapter allows for administration by either the patient or healthcare professional. ialuril is indicated to re-establish the glycosaminoglycan layers (gags) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as painful bladder syndrome (pbs), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of bacillus calmette ? guerin therapy, or chemical and radiation therapy. ialuril is also indicated in the cases where the loss of the glycosaminoglycan layers (gags) is associated with forms of chronic inflammation, in which their composition and integrity appears compromis

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - 44670 - bladder instillation, barrier - clear plastic pre-filled syringe containing a sterile aqueous solution of hyaluronic acid sodium salt (1.6%), sodium chondroitin sulphate (2%) and calcium chloride administered as a bladder instillation via a catheter. ialuril prefill is indicated to re-establish the glycosaminoglycan layers (gags) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as painful bladder syndrome (pbs), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of bacillus calmette ? guerin therapy, or chemical and radiation therapy. ialuril prefill is also indicated in the cases where the loss of the glycosaminoglycan layers (gags) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - galsulfase, quantity: 5 mg - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate heptahydrate; polysorbate 80; sodium chloride - for the long-term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi - n acetylgalactosamine 4-sulfatase deficiency)